TORONTO -(Dow Jones)- To cope with an ever-increasing workload, the U.S. Food and Drug Administration has authorized reviewers to miss some drug-approval deadlines by up to two months, which could explain why companies such as Cardiome Pharma Corp. (CRME) have yet to receive a decision from the agency.
